The CRUK Convergence Science Centre is a partnership between Imperial College London and The Institute of Cancer Research. In collaboration with our international partners we arrange a regular international seminar 'Converging on Cancer' on the topic of interdisciplinary cancer research. Our partners are
In this series, we bring together speakers from across these institutions to present their research and how they use convergence science to answer cancer-related questions. This session will be chaired by Assoc Prof Claus Storgaard Sørensen, BRIC - University of Copenhagen.
Thursday 6th Nov, 10-11am GMT, 11-12pm CET, 6-7pm SGT (N.B the change in time for SGT due to clock changes in Europe)
Prof Holger Auner (Lausanne University Hospital)
Targeting proteostasis and translation control in hematopoietic and solid cancers
In this seminar, Holger Auner will discuss recent and ongoing work in his lab on the role of the Integrated Stress Response (ISR) and GCN2, a highly conserved kinase that enables cells to adapt to various forms of proteostatic stress, such as the amino acid shortages caused by proteasome inhibition. He will present new insights into how cancer cells rely on GCN2 to regulate protein synthesis and maintain metabolic homeostasis — and how this dependency can be exploited as a potential therapeutic vulnerability.
Assoc Prof Morten Frödin (BRIC - University of Copenhagen)
CRISPR-Select: A fast, accurate and versatile functional-genetic assay to dissect the roles genes and variants/mutations in cancer
This talk will introduce CRISPR-Select, a simple and powerful functional-genetic assay for dissecting the roles of genes and mutations in cellular model systems. CRISPR-Select has been used to probe roles of genes (by introducing STOP variant), pathogenicity/driver roles of variants-of-uncertain-significance (VUS) in cancer genes, variant drug responsiveness/resistance, importance of phosphorylation/ubiquitination sites or in vivo tumor promotion by specific variants/cancer genes. Mechanistically, CRISPR-Select can dissect how a variant elicits a phenotype by causally linking the variant to motility/invasiveness or any cell state or biochemical process with a flow cytometry marker. The method is applicable to organoids, primary cells, non-transformed or cancer cell lines and we have scaled it for automated, higher-throughput 96-well plate format. Altogether, CRISPR-Select provides a versatile functional variant assay for research, diagnostics and drug development in cancer and other genetic disorders.
Researchers, students and anyone with an interest in convergence science relating to cancer research across our partnered institutions are welcome to register:
Please email icr-imperial-convergence.centre@imperial.ac.uk to receive the registration link.
If you are not a member of one of our partner institutions but would like to attend, please get in touch.
Leave a commentOrder by
Newest on top Oldest on top